9 research outputs found
POS0016 COMMON VARIABLE IMMUNODEFICIENCY DISEASE FROM THE PERSPECTIVE OF RHEUMATOLOGY
No full textBackgroundCommon variable immunodeficiency (CVID) is a primary immunodeficiency characterized by impaired B cell differentiation and immunoglobulin production. In addition to increased susceptibility to infection, patients also have an increased tendency to autoimmune disease. Since rheumatological findings usually start earlier than other autoimmunities, it is very important to increase the awareness of rheumatologists about this disease, for accurate diagnosis and to prevent delay in treatment.ObjectivesTo increase the awareness of rheumatologists about the main symptoms and findings of CVID.MethodsAdult patients referred to the rheumatology department since January 2015 were included in the study. Demographic and clinical characteristics (infections, pulmonary and extrapulmonary granulomatous involvement, autoimmune manifestations), laboratory and imaging findings and treatments of the patients were analyzed.ResultsTen adult patients with CVID were included in the study. The gender distribution of the patients was similar and the median age was 38±10.0 years. The mean duration of diagnosis was 123.5±89.3 months. At least one autoimmune manifestation was observed in 80% of the patients. In the follow-up period, 40% of the patients developed arthritis. Involvement of lower extremity joints such as knee and ankle was more prominent. While all patients were given 0.8 g/kg/3 weeks of intravenous immunoglobulin, 80% required immunosuppressive therapy for autoimmune manifestations. The demographic and clinical characteristics of the patients are summarized in Table 1.Table 1.Autoimmune manifestations of common variable immunodeficiency patientsCase 1Case 2Case 3Case 4Case 5Case 6Case 7Case 8Case 9Case 10Age/Sex36/F43/F40/M25/M23/M36/M41/M57/F35/F48/FSymptom duration (years)121111417121113127Diagnosis duration (years)61183171091112Sinopulmonary infection++++++++++GI infection-+-+-++---Other infections++-++-++-+Pulmonary Involvementlymphocytic ILDnodule*bronchiectasis--bronchiectasisbronchiectasiscavitationnodulenodule-Extrapulmonary Granulomabrain parenchyma, bone marrow, liver, spleen, skinliver, spleen-renal°, liver-**bone-ᵜlymph node--Autoimmune manifestations-monoarthritis,chronic ileitisoligoarthritis,atrophic gastritis,chronic ileitisalopecia, thyroiditis,bilateral anterior uveitis-oligoarthritis,autoimmune neutropenia,chronic ileitis,kounis syndromeoligoarthritis,autoimmune neutropeniaoligoarthritis, thyroiditis,sicca syndrome,recurrent scleritiscolitis-Cirrhosis of the liver++---+----Lymphadenopathy++++-+++++Splenomegaly++++-++-+-Immunosuppressive TreatmentSteroid, AZA, CSA, AdalimumabSteroidSteroid, SSZSteroid, MMF, CYC-Steroid, SSZ, MTX, LEF, CSASteroidSteroid, MTX, AZA, CSASteroid, AZA-Abbreviations: AZA-azathioprine, CSA-cyclosporine, CYC-cyclophosphamide, F-female, GI-gastrointestinal, ILD-interstitial lung disease, LEF-leflunomide, M-male, MTX-methotrexate, SSZ-sulfasalazine*right lower lobectomy, ** right foot 5th toe enucleation, ᵜ mediastinoscopic lymph node biopsy ° interstitial granulomatous nephritisConclusionAutoimmune diseases can be seen in patients with CVID, and sometimes this may be the first presentation of CVID. Heterogeneous clinical findings of the disease may lead to delay in diagnosis. Clinicians should be more careful about the different manifestations of CVID to avoid delay in diagnosis.Disclosure of InterestsNone declared</jats:sec
DO COMORBIDITIES IMPACT PERSISTENCE OF FIRST TUMOR NECROSIS FACTOR INHIBITOR TREATMENT IN RHEUMATOID ARTHRITIS? DATA FROM TURKBIO
No full textAnnual European Congress of Rheumatology (EULAR) -- JUN 03, 2020 -- ELECTR NETWORKAkkoc, Nurullah/0000-0002-3718-171XWOS: 000555905003171[No abstract available
DO COMORBIDITIES IMPACT PERSISTENCE OF FIRST TUMOR NECROSIS FACTOR INHIBITOR TREATMENT IN RHEUMATOID ARTHRITIS? DATA FROM TURKBIO
No full textDO COMORBIDITIES DECREASE THE FIRST TNF-INHIBITOR RETENTION AND TREATMENT RESPONSE IN AXIAL SPONDYLOARTHRITIS PATIENTS? DATA FROM TURKBIO
No full textCLINICAL FEATURES AND THE COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER
No full textThe Effect of Vedolizumab on Spondyloarthritis Symptoms in a Cohort of Inflammatory Bowel Disease Patients
No full textObjective: Vedolizumab is a novel anti-inflammatory molecule that is currently being used in the treatment of refractory inflammatory bowel disease. The mode of action is inhibiting the binding of activated T lymphocytes to the adhesion molecule 1 of intestinal mucosal cells. Due to its local effect, systemic immunosuppression is not expected, and this may have a negative effect on the extra-intestinal symptoms of inflammatory bowel disease, particularly spondyloarthritis. Currently, there is limited data regarding the effect of vedolizumab on spondyloarthritis symptoms. We aimed to investigate whether vedolizumab has an effect on the occurrence of rheumatological symptoms and the clinical course of patients who have spondyloarthritis. Methods: Thirty-nine adult inflammatory bowel disease patients who were followed up in the Gastroenterology Clinic and treated with vedolizumab were included in the study. Patients were reviewed in terms of rheumatological manifestations. The occurrence of new musculoskeletal findings during the vedolizumab treatment was recorded. Patients with a former diagnosis of spondyloarthritis were evaluated for the activity of axial and peripheral manifestations during the vedolizumab. Results: There were 39 inflammatory bowel disease patients (29 Crohn's disease, 10 ulcerative colitis, 48.7% (n = 19) male) who had been treated with vedolizumab. The mean age of the patients was 41.4 +/- 15.7 years, and the duration of inflammatory bowel disease was 10.4 +/- 7.5 years. A total of 17 (44%) patients had accompanying spondyloarthritis findings (mean age 47.08 +/- 15.325 years and 58.8% M). Seven patients had axial dominant symptoms and 6 of them were in an active disease state before vedolizumab. During vedolizumab, all but 1 continued to be active. There were 14 patients with arthritis/arthralgias before vedolizumab and only 3 had improvement with therapy. On the other hand, there were 3 patients who had new-onset arthralgias/arthritis with vedolizumab. In total, 6 patients needed to stop vedolizumab because of spondyloarthritis activation (n = 2) and uncontrolled inflammatory bowel disease (n = 4), respectively. Conclusion: Treatment with vedolizumab seems no effect on both the occurrence and the course of rheumatological manifestations in inflammatory bowel disease patients. Further studies are required to replicate our results
Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study
No full textClinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TNFi therapy in biologic naive patients diagnosed with LoAS. Patients whose age of onset was ≥ 45 years and < 45 years were classified as having LoAS and YoAS, respectively, based on the age of symptom onset. There were 2573 patients with YoAS and 281 LoAS. Baseline disease activity measures were similar between the groups. No significant differences were seen between the two groups in response to treatment and in remaining on the first TNFi at 6, 12 and 24 months. In the LoAS group, the analysis showed that TNFi discontinuation was linked to VAS pain score (HR 1.04; 95% CI 1.01–1.06). Patient groups had similar rates of adverse events (YoAS: 8.7% vs. LoAS: 11.7%). In both biologic naive LoAS and YoAS patients, the study showed that the initial TNFi therapy was equally effective and safe. © The Author(s) 2024
DO COMORBIDITIES DECREASE THE FIRST TNF-INHIBITOR RETENTION AND TREATMENT RESPONSE IN AXIAL SPONDYLOARTHRITIS PATIENTS? DATA FROM TURKBIO
No full textCOVID-19 VACCINATION OF SPONDYLOARTHRITIS PATIENTS RECEIVING BIOLOGICAL THERAPY: REAL-LIFE DATA
No full textBu çalışma, 01-04 Haziran 2022 tarihlerinde Copenhagen[Danimarka]’da düzenlenen Annual European Congress of Rheumatology (EULAR) Kongresi‘nde bildiri olarak sunulmuştur.European Alliance Assoc Rheumato
